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Abstract 
Background Data are limited on the safety and efficacy of robotic thymectomy in myasthenia 
gravis (MG) patients older than 60 years at onset.  
Methods Patients older than 60 years at MG onset who underwent robotic thymectomy in 
Charite Universitaetsmedizin Berlin between 2003 and 2017 were potentially eligible for 
inclusion. The main outcomes were perioperative complications and clinical outcome 
according to the MG Foundation of America Post-Intervention Status (MGFA-PIS).  
Results Sixty-eight (25 females, 43 males) of 580 MG patients who underwent robotic 
thymectomy were eligible for perioperative analyses (median age at MG onset 67 years [range 
61-85]). The perioperative morbidity rate was 13.2% and the only perioperative mortality was 
due to aortic dissection. Fifty-one patients were available for further analysis with a median 
follow-up time of 60 months (range 12-263). The complete stable remission (CSR) rate was 
7.8%, the improvement rate was 68.6% and the overall mortality rate was 11.8%. Compared 
with preoperative use, the average daily dose of corticosteroids was significantly reduced at 
the last follow-up (17.6±23.6 VS 2.6±6.1 mg, P=0.0001) without increased use of azathioprine 
(35.9±61.9 VS 42.7±59 mg, P=0.427). After excluding two patients seronegative for the anti-
acetylcholine receptor (AChR) antibody, 10 out of 49 seropositive patients achieved “good 
outcome” (including four CSR, three pharmacologic remission and three minimal 
manifestations 0) which was predicted by being free of concomitant disease (OR: 7.307, 95% 
CI (1.188-44.937), P=0.032) and MGFA classification I prethymectomy (OR: 6.696, 95% CI 
(1.259-35.620), P=0.026).  
Conclusion Robotic thymectomy seems to be safe and effective in MG patients older than 60 
years at onset with a significant steroid-sparing effect.  
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Introduction 
Myasthenia gravis (MG) is a rare autoimmune disorder characterized by muscle weakness 
caused by the production of autoantibodies against acetylcholine receptors (AChR) or other 
related molecules at the neuromuscular junction. The annual incidence of MG is estimated at 
8 to 10 per million population and the prevalence at 150 to 250 per million (1).  During the last 
few decades the incidence of MG in the elderly has been increasing worldwide (2-3). 
Thymectomy has become an indispensable option in the multidisciplinary management of MG 
since Blalock et al. first reported a complete remission of MG after thymectomy about 80 years 
ago (4). Since then, thymectomy has gained increasing acceptance and many approaches 
have been described (5, 6). As the latest advance of minimally invasive thymectomy, robotic 
thymectomy has been performed in patients with MG since 2003 (7). Available data have 
shown that minimally invasive thymectomy via video-assisted thoracoscopic surgery (VATS) 
approach or robotic-assisted approach can result in equivalent clinical outcome with reduced 
postoperative pain, less perioperative complications, quicker recovery and shorter hospital 
stay, when compared with extended transsternal thymectomy (8-10). Recently, a randomized 
controlled trial in MG patients aged between 18 and 65 years old demonstrated better clinical 
outcomes in patients who underwent extended transsternal thymectomy compared to those 
who did not (11). Regarding thymectomy in elderly MG patients, however, most researchers 
consider it as a risky and less effective intervention. 
In this study, we aimed to investigate the safety and efficacy of robotic thymectomy in MG 
patients older than 60 years at onset, providing evidence to counsel these patients who are 
contemplating undergoing thymectomy. 
Patients and Methods 
This is a monocentric observational retrospective study. The ethics approval for this study was 
granted by the Ethics Committee of Charite Universitaetsmedizin Berlin (Berlin, Germany). 
Written informed consent was obtained from each patient included in this study. 
We included patients with a confirmed diagnosis of MG, with disease onset after 60 years of 
age, who underwent robotic thymectomy at the thoracic surgery department in the Charite 
Universitaetsmedizin Berlin between 2003 and 2017. We excluded patients who were 60 years 
or younger at disease onset and patients with unspecified age at onset.  
The diagnosis of MG was confirmed by the presence of relevant clinical symptoms and either 
seropositive autoantibody status (mostly anti-AChR antibody [above 0.45 nM] or anti-muscle-
specific kinase [MuSK] antibody [above 0.4 U/ml]); response to acetylcholinesterase inhibitors; 
or positive electrophysiologic electrophysiologic findings (including repetitive nerve stimulation 
and single fiber electromyography) (12). Since thymoma is associated with MG in about 15% 
patients (13), a computed tomography (CT) scan of the chest was performed before 
thymectomy in all patients to screen for thymoma. Indication for thymectomy was not limited 
by age but poor general condition and geriatric multimorbidity, such as severe coagulopathy, 
recent myocardial infarction, pleural symphysis and poor lung function (FEV1 <30% and/or 
DLCO <30%).  
Patients without a suspected thymoma have been operated by a left-sided three-trocar 
approach for robotic thymectomy, in patients with a suspected thymoma a unilateral approach 
was chosen according to the location of the lesion. In rare cases, an extra trocar at subxiphoid 
was used to ensure the complete removal of the specimen. Typically, an enbloc resection 
including the thymus, thymoma (if any) and all mediastinal fatty tissue was performed by the 
authors. The “no touch” surgical technique was used in patients with a suspected thymoma.  
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Preoperative and perioperative data were collected retrospectively from the hospital 
information system, including the presence of concomitant disease (defined here as 
hypertension, dyslipidemia, diabetes mellitus [DM], coronary heart disease [CHD] and 
arrhythmia). Perioperative complications were reported according to a standardized 
classification system after thoracic surgery (14). We divided patients into two subgroups 
according to the presence of a thymoma, preoperative clinical parameters and perioperative 
parameters were compared between the two subgroups. 
After excluding patients with a follow-up less than 1 year, we assessed clinical status of the 
patients at a final follow-up using a structured telephone interview based on a questionnaire. 
In the case of patients who were not able to answer the questionnaire, we interviewed close 
family members who were familiar with the disease course. Based on the response to the 
questionnaire, we assessed the clinical state of the patients according to the MG Foundation 
of America Post-Intervention Status (MGFA-PIS), and divided patients into those who 
experienced a “good outcome” (defined as complete stable remission [CSR], pharmacologic 
remission [PR] and minimal manifestations 0 [MM-0]), or “poor outcome” (minimal 
manifestations 1-3 [MM 1-3]). 
SPSS 21.0 software (IBM Corp., Armonk, NY, USA) and GraphPad Prism 5.0 software 
(GraphPad Software, Inc., La Jolla, CA, USA) were used to perform the statistical analyses. 
Continuous variables were summarized as median (range) and analyzed by Mann Whitney 
test, whilst categorical variables were summarized as proportions and analyzed by Chi-
Squared test or Fisher’s Exact test. Missing data were treated as unknown data points, but the 
medications of the six deceased patients at the last follow-up were handled via last observation 
carried forward approach. Binary logistic regression models were performed to determine the 
association of clinical characteristics with “good outcome” of robotic thymectomy in MGpatients 
older than 60 years at onset. Variables with a P value smaller than 0.1 on univariate analyses 
were included in the multivariable binary logistic regression model and P<0.05 was considered 
statistically significant. 
 
Results 
Five hundred and eighty patients with MG underwent robotic thymectomy in the Charite 
Universitaetsmedizin Berlin between 2003 and 2017 (Figure 1). After excluding 395 patients 
who were 60 years or younger at MG onset and 117 with unspecified age at onset, 68 patients 
were older than 60 years at MG onset. The series comprised 25 females (37%) and 43 males 
(63%) with a median age at MG onset of 67 years (range 61-85). Table 1 shows the detailed 
preoperative clinical parameters of patients with thymomatous MG and non-thymomatous MG. 
In our series, the female:male ratio was significantly different between thymomatous MG 
(1.27:1) and non-thymomatous MG (0.34:1) (P=0.012). There were also statistical differences 
between the two groups in symptoms at onset (P=0.036), thymectomy delay (P=0.022) and 
medications (P=0.010). 
Table 2 summarizes perioperative clinical parameters in patients with thymomatous MG and 
non-thymomatous MG. There were no significant differences. One out of 68 patients 
underwent a conversion to median sternotomy for the injury of the left innominate vein. The 
median length of hospital stay in our series was 5 days (range 2-77). The patient with a 77 
days of hospital stay experienced worsening symptoms after thymectomy and died of MG. 
Perioperative complications occurred in 9 out of 68 patients and are described in Table 3 
according to Seely et al. (14). Among the nine patients with perioperative complications, one 
also experienced perioperative MG crisis and was treated with plasmapheresis. Thymic 
follicular hyperplasia occurred in six (14%) non-thymomatous MG patients, leaving 37 (86%) 
 5 
 
findings of involution. In 25 thymomatous MG, follicular hyperplasia was found in six (24%) 
residual glands, and involution was found in the rest (76%). 
After excluding 4 patients with a follow-up less than 1-year and 13 patients who were lost to 
the last follow-up, 51 patients were available for further analyses with a median follow-up time 
of 60 months (range 12-263). There were no significant differences between the two subgroups 
with regard to clinical outcomes (Table 4). Ten patients had a “good outcome” at the last follow-
up: four CSR, three PR and three MM-0. Thirty-five of 51 (68.6%) patients showed 
improvement after robotic thymectomy, leaving eight unchanged, four worse and four died of 
MG. The other two death were due to stroke 39 months after surgery and myocardial infarction 
42 months after surgery (Table 5). 
The average number of medications required for MG decreased at the last follow-up, compared 
with the preoperative period (Figure 2A, 1.9±0.9 VS 1.5±0.8, P=0.025). Although the average 
daily dose of corticosteroids decreased significantly (Figure 2C, 17.6±23.6 VS 2.6±6.1 mg, 
P=0.0001), the average daily doses of cholinesterase inhibitors (Figure 2B, 252.7±183.2 VS 
205.5±176.0 mg, P=0.154) and azathioprine (Figure 2D, 35.9±61.9 VS 42.7±59.0 mg, P=0.427) 
did not change statistically between the preoperative period and at the last follow-up. However, 
three patients who used to take azathioprine were taking mycophenolat mofetil at the last 
follow-up because of the side effects of azathioprine (leukopenia and liver function test 
abnormalities), and medications of the six deceased patients at the last follow-up were 
replaced by their last observational ones. 
Since there were only two patients seronegative for anti-AChR antibody, we conducted binary 
logistic regression models to identify clinical parameters associated with “good outcome” in 
forty-nine seropositive patients. Univariate analyses identified being free of concomitant 
disease (Table 6, OR: 5.583, 95% CI (1.138-29.899), P=0.034), purely ocular symptoms at 
onset (Table 6, OR: 5.575 (1.076-30.720), P=0.041) and MGFA classification I prethymectomy 
(Table 6, OR: 5.500(1.210-25.005), P=0.027) as potential predictors of “good outcome”. In a 
multivariable analysis, being free of concomitant disease (Table 6, OR: 7.307, 95% CI (1.188-
44.937), P=0.032) and MGFA classification I prethymectomy (Table 6, OR: 6.696, 95% CI 
(1.259-35.620) P=0.026) persisted as independent predictors of “good outcome” after 
thymectomy. Besides, the predictive factors remained the same when we added back the two 
seronegative cases in the analyses. 
Comment 
To our knowledge, this monocentric retrospective study is the largest series describing the 
safety and efficacy of robotic thymectomy in patients older than 60 years at MG onset. In our 
series, men (n=43) outnumbered women (n=25), mainly due to more men developing non-
thymomatous MG, which is in line with previous report (3). Besides, patients with thymomatous 
MG had a shorter thymectomy delay (P=0.022), smaller probability of purely ocular symptoms 
at onset (P=0.036) and required fewer immunosuppressive medications (P=0.010) compared 
with patients with non-thymomatous MG, similar to a previous study (15). In our series, the 
percentage (70.6%) of the MG patients older than 60 years at onset who required 
immunosuppressive medications was comparable with that (65% to 82.1%) reported 
previously (16-18). Therefore, it would be advantageous if evidence on steroid-sparing effect 
of robotic thymectomy in this population could be provided. 
The rate of open conversion in our series was 1.5%, which was similar to that (2.4%, 3.1%) 
reported in previous publications (19, 20). The only conversion in our series occurred in a 73 
years male with a 7.7cm Masaoka-Koga stage III thymoma because of the injury of the left 
innominate vein. The perioperative complication rate of 13.2% was similar to that (15.4%) in a 
non-robotic thymectomized series including 34 patients older than 50 years at MG onset (21), 
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but higher than that (5%) in a thoracoscopic thymecomized series with an average age of 29 
years at MG onset (22). Another study of 28 cervicomediastinal thymectomized patients older 
than 55 years also reported a pulmonary complication rate of 5.5% and one mortality because 
of a pulmonary embolism 3 days after discharge from the hospital (23). The overall mortality 
rate in our series was 11.8% with a MG specific mortality of 7.8%, which is in line with that 
(13%) reported in another elderly series (24), but higher than that (0%) in a younger series 
(22). Therefore, from our experience, robotic thymectomy in MG patients older than 60 years 
at onset seems to be as safe as non-robotic thymectomy, although might not be as safe as in 
a non-elderly population. However, comorbidities should be carefully evaluated and 
considered in the decision making towards thymectomy in patients with non-thymomatous MG. 
Patients with multimorbidity increasing perioperative risk or reducing the long-term prognosis 
substantially should be excluded from thymectomy (25).  
In 1975, Perlo et al. found 9 cases with involuted thymic tissues and 11 without thymic tissues 
in 20 autopsies from patients older than 60 years, concluding that thymecotmy is not likely to 
be effective in this population (26). However, in recent thymectomy series, thymic hyperplasia 
was seen in 5/39 (12.8%) patients older than 50 years at MG onset (21), in 8/28 (28.6%) 
patients older than 55 years at onset (23) and in 4/25 (16%) patients older than 60 years at 
onset (24). Similarly, the rate of thymic hyperplasia in our non-thymomatous MG was 6/43 
(14%). Although most of the non-thymomatous MG patients older than 60 years at onset were 
likely to present with involuted thymus, the authors did not see refusal reasons for thymectomy 
in this population. First, it is still controversial whether evoluted thymus plays a prognostic role 
in MG patients (27, 28). Second, MG patients with involuted thymus could be seropositive for 
anti-AChR antibodies and previous studies have demonstrated that ectopic thymic tissue is 
likely to be the place where the antibodies are produced in these patients (29-32). Third, 
although thymectomy was deemed less effective in late-onset MG than in early-onset MG 
patients, data comparing clinical outcomes between surgical patients and non-surgical controls 
in MG patients older than 60 years at onset are still limited. 
In our series, four patients (7.8%) achieved CSR and 35 patients (68.6%) showed improvement 
after thymectomy according to the MGFA-PIS, which is comparable with outcomes reported 
previously in series of elderly patients who underwent extended thymectomy or 
cervicomediastinal thymectomy (23, 24). Although the rate of remission in elderly MG patients 
after thymectomy was lower than that reported in non-elderly patients, the rate of improvement 
was still comparable (22). Importantly, we found that the average daily corticosteroids dose 
had statistically decreased (P=0.0001) after thymecomy without increasing the average daily 
dose of azathioprine (P=0.427), which was the most commonly used steroid-sparing drug in 
our series. Therefore, we deemed that robotic thymectomy was effective for MG patients older 
than 60 years at onset regarding the long-term neurologic outcome and the steroid-sparing 
effect. 
Being free of concomitant disease and MGFA classification I prethymectomy were 
independently associated with “good outcome” in our patients. A systematic review also found 
that preoperative mild disease severity is the most repeatedly reported predictor of remission 
(28). Although many researchers believe that patients with thymic follicular hyperplasia are 
more likely to benefit from thymectomy (33-34), neither thymic follicular hyperplasia nor 
thymoma was associated with “good outcome” in our series, which is also in line with the 
findings of the systematic review (28). 
This study has some limitations. Data were collected retrospectively from the hospital 
information system, and most missing data were treated as unknown data points. This is a 
single arm case series, the absence of the comparison is a major limitation of our research. 
We have not systematically assessed the number of patients having refused thymecomy which 
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is a further limitation of our study. Besides, 13 out of 64 (20.3%) patients were lost to follow-
up, which also introduced selection bias in this study. Furthermore, patients were not treated 
by the same neurologist after thymectomy. Also, at the last follow-up, azathioprine was 
replaced by mycophenolat mofetil in three patients due to side-effects and data for six 
deceased patients were handled via the last observation carried forward approach, which 
might introduce bias when evaluating the steroid-sparing effect in this study. Since myasthenic 
symptoms could be changing over time and some patients might even re-suffer from the 
symptoms after reaching complete stable remission, this adds difficulty in interpreting the 
results of our research and is another limitation of our research. Finally, the sample size was 
too small to draw solid conclusions. However, considering the rarity of the disease, it is virtually 
impossible to conduct a randomized controlled trial in MG patients older than 60 years at onset, 
and this is a relatively large series of patients treated using the same surgical technique at a 
single center. In addition, all patients were well documented during their treatment and followed 
based on a well-constructed questionnaire. 
Robotic thymectomy seems to be safe and effective in patients older than 60 years at MG 
onset with a significant steroid-sparing effect. In this population, being free of concomitant 
disease and MGFA classification I prethymectomy appear to be independently associated with 
“good outcome”. 
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Table. 1 Preoperative clinical parameters of 68 patients older than 60 years at MG onset 
Clinical parameters Total MG with or without Thymoma P Value 
 (N=68) Thymomatous 
MG (n=25) 
Non-
thymomatous  MG 
(n=43) 
Gender, no. (%)    0.012 
Male 43(63.2%) 11(44%) 32(74.4%)  
Female 25(36.8%) 14(56%) 11(25.6%)  
Age at onset, median 
(range), yrs 
 67 (61-85) 68 (61-85) 67 (61-82) 0.601 
BMI a , median (range), 
Kg/m2 
26 (18.1-
51.1) 
24.5 (18.1-
51.1) 
26.6 (19.2-39.8) 0.090 
Anti-AChR Ab, no. (%)    0.292 
Positive 65(95.6%) 25(100%) 40(93%)  
Negative 3(4.4%) 0(0%) 3(7%)  
OAID, no. (%)    0.074 
Yes 21(30.9%) 11(44%) 10(23.3%)  
No 47(69.1%) 14(56%) 33(76.7%)  
Concomitant disease, no. 
(%) 
   0.305 
Yes 57(83.8%) 19(76%) 38(88.4%)  
No 11(16.2%) 6(24%) 5(11.6%)  
Symptoms at onset, no. 
(%) 
   0.036 
Purely ocular symptoms 32(47.1%) 8(32%) 24(55.8%)  
Others 34(50%) 17(68%) 17(39.5%)  
Unknown 2(2.9%) 0(0%) 2(4.7%)  
MGFA classification, no. 
(%) 
   0.204 
I 13(19.1%) 7(28%) 6(14%)  
II-V 55(80.9%) 18(72%) 37(86%)  
MG crisis, no. (%)    1.000 
Yes 12(17.6%) 4(16%) 8(18.6%)  
No 56(82.4%) 21(84%) 35(81.4%)  
ThX delay, median 
(range), Mons 
9 (1-168) 4 (1-35) 13 (2-168) 0.022 
Medications, no. (%)    0.010 b 
No medications 3(4.4%) 3(12%) 0(0%)  
Cholinesterase inhibitors 17(25%) 9(36%) 8(18.6%)  
Corticosteroids 24(35.3%) 9(36%) 15(34.9%)  
Steroid-sparing drugs 5(7.4%) 1(4%) 4(9.3%)  
Both 19(27.9%) 3(12%) 16(37.2%)  
Plasmapheresis and/or IVIg, 
no. (%) 
9(13.3%) 3(12%) 6(14%) 1.000 
a. Data were available for 59 patients (21 thymomatous MG and 38 non-thymomatous 
MG). 
b. Patients who received immunosuppressive medications vs. patients did not, calculated 
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by Chi-Squared test. 
BMI = body-mass-index; Anti-AChR Ab = antibody against acetylcholinesterase receptor; 
OAID = other autoimmune disease; ThX = thymectomy; IVIg = IV immunoglobulin. 
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Table. 2 Perioperative clinical parameters of 68 patients older than 60 years at MG onset 
Clinical parameters Total MG with or without Thymoma P 
value  (N=68) Thymomatous 
MG (n=25) 
Non-
thymomatous  
MG (n=43) 
Open conversion    0.368 
Yes 1(1.5%) 1(4%) 0(0%)  
No 67(98.5%) 24(96%) 43(100%)  
Length of hospital stay, median 
(range), d 
5(2-77) 6(3-20) 5(2-77) 0.085 
Complications a, no. (%)    0.272 
None 59(86.8%) 20(80%) 39(90.7%)  
Yes 9(13.2%) 5(20%) 4(9.3%)  
Minor 5(55.6%) 3(60%) 2(50%)  
Major 3(33.3%) 2(40%) 1(25%)  
Mortality 1(11.1%) 0(0%) 1(25%)  
Weight of the specimen b, median 
(range), g 
102 (20-
280) 
87.5 (35-280) 116 (20-274) 0.299 
Pathology of the thymus c, no. (%)    0.335 
Involution 56(82.4%) 19(76%) 37(86%)  
Follicular hyperplasia 12(17.6%) 6(24%) 6(14%)  
a. Documented according to Seely et al. (14). 
b. Data were available for 54 patients (20 thymomatous patients and 34 non-
thymomatous patients). 
c. In thymomatous MG, pathology of the residual gland was detected. 
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Table. 3 Clinical parameters of 9 patients who experienced postoperative complications 
Gender Age at 
onset, 
yrs 
Delay 
of 
ThX, 
mons. 
MGFA 
class 
Thymic 
pathology 
Complication Grade Conconmitant 
disease 
preThX 
Male 79 6 I Involution Delirium I No 
Male 72 3 IIa Thymoma 
with 
involution 
Tachycardias II Hypertension 
Male 73 1 IIb Thymoma 
with 
involution 
Atrial 
fibrillation 
II No 
Male 66 2 IIb Involution Atrial 
fibrillation 
II CHD, DM, 
Hypertension, 
Arrhythmia 
Female 66 14 IIa Thymoma 
with 
involution 
Pulmonary 
artery 
embolism 
II Hypertension 
Male 70 15 IIb Hyperplasia Bradycardia IIIa DM 
Male 72 3 I Thymoma 
with 
involution 
Pleural 
effusion and 
MG crisis 
IIIa Hypertension 
Female 62 4 I Thymoma 
with 
involution 
Respiratory 
failure 
IVa Hypertension, 
DM 
Male 74 9 IIb Hyperplasia Type A aortic 
dissection  
V Hypertension 
ThX = thymectomy. 
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Table. 4 Clinical outcome of 51 patients older than 60 years at MG onset 
Clinical parameters Total MG with or without Thymoma P 
value  (N=51) Thymomatous 
MG (n=19) 
Non-
thymomatous  
MG (n=32) 
MGFA-PIS    1.000 
Good outcome 10(19.6%) 4(21.1%) 6(18.8%)  
Poor outcome 41(80.4%) 15(78.9%) 26(81.2%)  
Change in status    0.517 a 
Improved 35(68.6%) 12(63.2%) 23(71.9%)  
Unchanged 8(15.7%) 4(21.1%) 4(12.5%)  
Worse 4(7.8%) 2(10.5%) 2(6.3%)  
Died of MG 4(7.8%) 1(5.3%) 3(9.4%)  
Medications, no. (%)    0.517 b 
No medications 5(9.8%) 1(5.3%) 4(12.5%)  
Cholinesterase inhibitors 11(21.6%) 6(31.6%) 5(15.6%)  
Corticosteroids 9(17.6%) 4(21.1%) 5(15.6%)  
Steroid-sparing drugs 21(41.2%) 6(31.6%) 15(46.9%)  
Both 5(9.8%) 2(10.5%) 3(9.4%)  
a. Improved vs. others calculated by Chi-Squared Test. 
b. Patients received immunosuppressive medications vs. patients did not, calculated by 
Chi-Squared Test. 
 
MGFA-PIS = Myasthenia Gravis Foundation of America Post-Intervention Status. 
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Table. 5 Clinical parameters of the six deceased patients 
Gender Age at 
onset, 
yrs 
ThX 
delay, 
mons. 
MGFA 
classification 
Thymic 
pathology 
Specific reason 
of death  
Overall 
survivala, 
mons. 
Male 74 9 IIb Hyperplasia MG 9 
Male 69 3 IIb Thymoma with 
involution 
MG 14 
Male 78 5 I Involution Stroke 44 
Female 81 7 IIb Thymoma with 
involution 
Myocardial 
infarction 
49 
Male 78 10 IIIb Involution MG 51 
Male 71 168 V Involution MG 180 
a. From disease onset to death. 
 
ThX= thymectomy  
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Table. 6 Binary logistic regression of clinical parameters associated with a “good outcome” in 
49 patients seropositive for anti-AChR antibody 
 
Variable 
Univariate analysis Multivariable analysis 
OR (95% CI) P value OR (95% CI) P value 
Age at onset, yrs 1.063(0.953-1.186) 0.270 NA NA 
Female 0.400(0.075-2.143) 0.285 NA NA 
BMI, kg/m2 0.891(0.725-1.095) 0.272 NA NA 
Being free of OAID 4.500(0.513-
39.436) 
0.174 NA NA 
Being free of concomitant 
disease 
5.833(1.138-
29.899) 
0.034 7.307(1.188-
44.937) 
0.032 
Purely ocular symptoms at 
onset  
5.575(1.076-
30.720) 
0.041 NA NA 
ThX delay, mons 0.958(0.877-1.046) 0.339 NA NA 
MGFA classification I preThX 5.500(1.210-
25.005) 
0.027 6.696(1.259-
35.620) 
0.026 
Thymic follicular hyperplasia a 1.333(0.113-
15.704) 
0.819 NA NA 
Thymoma 1.095(0.262-4.572) 0.901 NA NA 
a. Reference = thymic involution 
 
OR = odds ratio; CI = confidence interval; NA = not applicable; BMI = body-mass-index; OAID 
= other autoimmune disease; ThX = thymectomy. 
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Figure 1. Age split of MG patients who underwent robotic thymectomy between 2003 and 2017 
in Charite Universitaetsmedizin Berlin. Five hundred and eighty patients with MG underwent 
robotic thymecotmy, among whom 463 patients had documented age at disease onset. Sixty-
eight out of 463 patients were older than 60 years at MG onset.  
Figure 2. Average daily medications of the MG patients older than 60 years at onset during 
the preoperative period and at last follow-up (n=51). Medications of the six deceased patients 
were handled via Last Observation Carried Forward approach. A. Average number of daily 
medications for MG during the preoperative period and at the last follow-up. B-D. Average 
daily dose of cholinesterase inhibitors (B), corticosteroids (C), azathioprine (D) during the 
preoperative period and at the last follow-up. 
